AMRX
Amneal Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$19.31
−4.45%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 3.2B | 3.0B | 2.8B | 2.4B | 2.2B |
| Cost of Revenue | 1.9B | 1.9B | 1.8B | 1.5B | 1.4B |
| Gross Profit | 1.3B | 1.1B | 1.0B | 863.9M | 791.5M |
| Operating Expenses | |||||
| R&D Expense | 182.7M | 186.2M | 190.7M | 194.8M | 208.7M |
| SG&A Expense | 573.7M | 526.8M | 476.4M | 429.7M | 399.7M |
| General & Admin Expense | — | — | 442.0M | 417.3M | 382.9M |
| Selling & Marketing Expense | — | — | 34.4M | 12.4M | 16.8M |
| Other Expenses | 1.7M | — | 104.0M | 35.1M | 278.0M |
| Total Operating Expenses | 758.0M | 713.0M | 771.1M | 659.5M | 886.4M |
| Cost and Expenses | 2.7B | 2.6B | 2.5B | 2.2B | 2.3B |
| Operating Income (EBIT) | 527.9M | 423.1M | 249.3M | 204.4M | (94.9M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | 223.6M | 241.1M | 258.6M | 210.6M | 158.4M |
| Net Interest Income | (223.6M) | (241.1M) | (258.6M) | (210.6M) | (158.4M) |
| Other Non-Op Income/Expense | (306.4M) | (283.9M) | (304.3M) | (244.6M) | (153.2M) |
| Non-Operating Income (excl Interest) | 3.0M | 42.8M | 45.7M | (67.0M) | (295.0M) |
| EBT (Pre-Tax Income) | 221.5M | 139.2M | (55.0M) | (40.3M) | (248.1M) |
| Income Tax Expense | 12.0M | 11.3M | 18.9M | 8.5M | 6.7M |
| Bottom Line | |||||
| Net Income | 133.3M | 72.1M | (116.9M) | (84.0M) | (130.0M) |
| Earnings from Cont. Ops | 209.5M | 127.9M | (73.9M) | (48.7M) | (254.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 133.3M | 72.1M | (116.9M) | (84.0M) | (130.0M) |
| Per Share | |||||
| Basic EPS | $0.43 | $0.23 | ($0.38) | ($0.48) | ($0.86) |
| Diluted EPS | $0.42 | $0.22 | ($0.38) | ($0.48) | ($0.86) |
| Revenue Per Share | $9.52 | $9.63 | $9.04 | $13.68 | $14.66 |
| Shares | |||||
| Basic Shares Outstanding | 335.7M | 313.4M | 309.0M | 175.0M | 150.9M |
| Diluted Shares Outstanding | 335.7M | 324.8M | 309.0M | 176.1M | 150.9M |
| Profitability Metrics | |||||
| EBITDA | 539.9M | 603.9M | 439.8M | 500.8M | 440.2M |
| D&A | 193.5M | 223.6M | 236.2M | 229.4M | 240.2M |
| EBIT | 524.9M | 380.3M | 203.6M | 271.4M | 200.0M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026